Ziel
Diabetes is a major health problem in Europe. Limited availability of donor tissue restricts conventional transplant treatments. Therefore, we propose to bioengineer pancreatic islet microorgans (called pseudoislets) using glucose-responsive insulin-producing cells of differentiated stem cell origin. These microorgans should be suitable substitutes to restore the function of the destroyed pancreatic islets in a diabetic individual. The combination of the bioengineering of insulin-secreting surrogate cells with techniques for generation of a pancreatic islet microorgan represents a highly innovative experimental approach. This Cell Factory concept for an innovative insulin replacement therapy, applied to cells of human origin, can offer, due to the unlimited supply, a cure to many diabetic patients. The long-standing expertise and experience of the partners in this proposal bring together the capabilities to achieve this highly desirable goal.
Wissenschaftliches Gebiet
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Data not availableFinanzierungsplan
CSC - Cost-sharing contractsKoordinator
30625 HANNOVER
Deutschland